Industry news
-
16 May 2017
New technology could dramatically shorten diagnosis time of stroke patients
Sarah Wills / European Pharmaceutical Review
An ambitious collaboration between Brainomix, an emerging British business, and Boehringer Ingelheim, one of the world’s largest drug companies, is poised to expedite and improve treatment of stroke, the second biggest killer disease in Europe.
-
15 May 2017
John Carroll / Endpoints News
Over the last few months we’ve seen a string of big and small biopharma companies make public pledges to keep their annual drug price hikes limited to modest annual increases. But looking back over 2016, one gauge of drug price inflation highlights that the trends all point to only a modest “softening” of the hard price spikes the US has been seeing for years now.
-
15 May 2017
Pfizer expands gene therapy effort on hemophilia, bagging rights to a Sangamo drug in a $545M deal
John Carroll / Endpoints News
With one gene therapy for hemophilia B well along the way in the clinic at Spark Therapeutics, pharma giant Pfizer $PFE is now extending its interest in the field With one gene therapy for hemophilia B well along the way in the clinic at Spark Therapeutics, pharma giant Pfizer $PFE is now extending its interest in the field with a pact with Sangamo on a new gene therapy for hemophilia A.with a pact with Sangamo on a new gene therapy for hemophilia A.
-
12 May 2017
WHO Launches Biosimilar Pilot Program
BioPharm International
The World Health Organization (WHO) is launching a pilot project to make biosimilars for the treatment of cancer more widely available in low- and middle-income countries. In a May 4, 2017 press release, WHO said that in September 2017 it will be inviting manufactures to submit applications for prequalification of biosimilar versions of rituximab and trastuzumab, both of which are on the WHO Essential Medicines List.
-
12 May 2017
EMA and EU Member States Begin Brexit Discussions
BioPharm Internationa
On April 28, 2017, the European Medicines Agency announced that it met with members of the heads of the National Competent Authorities (NCAs) of the member states of the European Union to discuss the United Kingdom’s exit from the EU (Brexit) and how the agency and the member states will handle the evaluation and monitoring of drugs going forward. EMA stated in a press release that, although Brexit actions have not officially begun, the agency will proceed under the assumption that the UK will no longer participate in the European regulatory system as of March 30, 2019. -
11 May 2017
Neothetics Provides Business Update and Reports First Quarter 2017 Financial Results
Neothetics , Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market today provided a business update and reported financial results for the first quarter 2017.
-
11 May 2017
More pharma in pharmacy? McCann Health suggests closer relationships
Beth Snyder Bulik / FiercePharmaMarketing
Pharmacies remain an untapped frontier for pharma companies as they evolve into one-stop patient shops for health and wellness needs, according to a new white paper from McCann Health. And pharma should take note.
-
11 May 2017
CBER Director Focuses on Flexibility to Advance Regenerative Medicines
Michael Mezher / Regulatory Affairs Professionals Society
Peter Marks, director of the US Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) on Thursday said his office is equipped to support the development of cutting edge treatments, such as cell and gene therapies.
-
10 May 2017
Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today reported financial results for the quarter ended March 31, 2017 and provided an update on its development programs.
-
10 May 2017
John Carroll / Endpoints News
To hear analysts at the QuintilesIMS Institute tell it, 2016’s sudden plunge in new drug approvals was an aberration that won’t be repeated anytime over the next five years. In their new, annual drug spending report, the analysts at this group determined that the industry pipeline is brimming full and likely to spew out 40 to 45 new drug approvals every year from this year through 2022, returning to a level set in 2014 and 2015.
All Portfolio
MEDIA CENTER
-
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.